Humacyte (HUMA) to Release Earnings on Friday

Humacyte (NASDAQ:HUMA - Get Free Report) is expected to be releasing its Q4 2024 earnings data before the market opens on Friday, March 28th. Analysts expect Humacyte to post earnings of ($0.23) per share and revenue of $0.64 million for the quarter. Persons that are interested in registering for the company's earnings conference call can do so using this link.

Humacyte (NASDAQ:HUMA - Get Free Report) last posted its quarterly earnings data on Friday, March 28th. The company reported ($0.16) earnings per share for the quarter, beating the consensus estimate of ($0.23) by $0.07. On average, analysts expect Humacyte to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Humacyte Stock Down 2.5 %

NASDAQ:HUMA traded down $0.05 during midday trading on Friday, hitting $1.96. The company had a trading volume of 11,968,972 shares, compared to its average volume of 3,333,918. The stock's fifty day moving average price is $3.61 and its 200-day moving average price is $4.50. Humacyte has a 52-week low of $1.76 and a 52-week high of $9.97. The company has a market capitalization of $246.68 million, a PE ratio of -1.46 and a beta of 1.36.

Analyst Upgrades and Downgrades

HUMA has been the topic of a number of research reports. D. Boral Capital reissued a "buy" rating and set a $25.00 price objective on shares of Humacyte in a report on Wednesday. HC Wainwright reaffirmed a "buy" rating and issued a $15.00 price objective on shares of Humacyte in a research note on Wednesday, March 12th. Finally, Benchmark reissued a "buy" rating on shares of Humacyte in a research note on Thursday, February 27th. One analyst has rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Buy" and an average price target of $13.71.

Remove Ads

Humacyte Company Profile

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.